All In Biotech

Drug Trial Radar · NCT07597629

A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer

A Phase II Clinical Study Evaluating the Efficacy and Safety of SYS6023 Combination Therapy for Unresectable Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

May 25, 2026

Primary completion

Nov 30, 2027

Study completion May 30, 2029

Sponsor

Sponsor type
Industry
First posted
May 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter Phase II clinical study conducted in subjects with advanced breast cancer.

Conditions

  • Advanced Breast Cancer

Interventions

  • SYS6023Drug

    SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.

  • KN026Drug

    KN026 is an antibody targeting HER2, administered via intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of dose-limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days).
  2. Frequency and severity of AEs and SAEs (according to NCI-CTCAE 6.0);Time frame: Baseline up to 28 days post last dose, Up to approximately 3 years
  3. Recommended Phase 2 Dose(RP2D)Time frame: Up to approximately 3 years
  4. Objective Response Rate (ORR)Time frame: Up to approximately 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Tumor Hospital of Harbin

    Harbin, Heilonjiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.